Friday - July 31, 2026
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
February 11, 2026
SANTA CLARA, California, Feb. 11 [Category: BizLaboratory Sciences] -- Agilent Technologies, a company that specializes in life sciences, diagnostics and applied chemical markets, issued the following news release:

* * *

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

*

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administrat . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products